Clinical Trial Update: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 safety and preliminary efficacy study of CC-99282 in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CC-99282
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED